Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/29/2871076/0/en/Cullinan-Therapeutics-Announces-Appointment-of-Mary-Kay-Fenton-as-Chief-Financial-Officer.html
https://finance.yahoo.com/news/why-cullinan-therapeutics-stock-trading-202917676.html
https://www.globenewswire.com/news-release/2024/04/24/2868766/0/en/Cullinan-Therapeutics-to-Present-Clinical-Data-from-Phase-1-Study-Evaluating-Novel-Anti-MICA-B-Antibody-CLN-619-as-Monotherapy-and-in-Combination-with-a-Checkpoint-Inhibitor-in-Pat.html
https://www.biopharmadive.com/news/cullinan-oncology-autoimmune-lupus-strategy-shift/713296/
https://www.globenewswire.com//news-release/2024/03/14/2846138/0/en/Cullinan-Oncology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/01/2838731/0/en/Cullinan-Oncology-Announces-U-S-FDA-Clearance-of-Investigational-New-Drug-Application-for-Novel-MICA-B-Antibody-CLN-619-for-Relapsed-Refractory-Multiple-Myeloma.html
https://www.globenewswire.com//news-release/2023/12/18/2798167/0/en/Cullinan-Oncology-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/12/14/2796727/0/en/Cullinan-Oncology-Announces-First-Patient-Dosed-in-Phase-1-Trial-Evaluating-CLN-617-a-Novel-Fusion-Protein-Uniquely-Harnessing-Both-IL-2-and-IL-12-Cytokines.html
https://www.globenewswire.com//news-release/2023/11/08/2776057/0/en/Cullinan-Oncology-Provides-Corporate-Update-and-Reports-Third-Quarter-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2023/11/03/2773339/0/en/Cullinan-Oncology-to-Present-Data-Demonstrating-Progress-Across-Its-Broad-Immunotherapy-Pipeline-at-SITC-2023.html